Butler T, Sridhar C B, Daga M K, Pathak K, Pandit R B, Khakhria R, Potkar C N, Zelasky M T, Johnson R B
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock 79430, USA.
J Antimicrob Chemother. 1999 Aug;44(2):243-50. doi: 10.1093/jac/44.2.243.
To compare the clinical and bacteriological efficacies of azithromycin and chloramphenicol for treatment of typhoid fever, 77 bacteriologically evaluable adults, with blood cultures positive for Salmonella typhi or Salmonella paratyphi A susceptible to their assigned drugs, were entered into a randomized open trial at four hospitals in India. Forty-two patients were randomized to receive azithromycin 500 mg p.o. od for 7 days and 35 to receive chloramphenicol 2-3 g p.o. od in four divided doses for 14 days. Thirty-seven patients (88%) in the azithromycin group responded with clinical cure or improvement within 8 days and 30 patients (86%) in the chloramphenicol group responded with cure or improvement. By day 14 after the start of treatment, all patients treated with azithromycin and all except two of the patients treated with chloramphenicol (94%) were cured or improved. Blood cultures repeated on day 8 after start of therapy showed eradication of organisms in 100% of patients in the azithromycin group and 94% of patients in the chloramphenicol group. By day 14 the eradication rate in the chloramphenicol group had increased to 97%. Stool cultures on days 21 and 35 after start of treatment showed no prolonged faecal carriage of Salmonella spp. in either group. These results indicate that azithromycin given once daily for 7 days was effective therapy for typhoid fever in a region endemic with chloramphenicol-resistant S. typhi infection and was equivalent in effectiveness to chloramphenicol given to patients with chloramphenicol-susceptible infections.
为比较阿奇霉素和氯霉素治疗伤寒热的临床及细菌学疗效,77名细菌学评估合格的成年人(血培养显示伤寒沙门菌或甲型副伤寒沙门菌阳性且对分配给他们的药物敏感)在印度的四家医院参加了一项随机开放试验。42名患者随机接受阿奇霉素500毫克口服,每日一次,共7天;35名患者接受氯霉素2 - 3克口服,每日一次,分四次服用,共14天。阿奇霉素组37名患者(88%)在8天内临床治愈或改善,氯霉素组30名患者(86%)治愈或改善。治疗开始后第14天,所有接受阿奇霉素治疗的患者以及除两名患者外所有接受氯霉素治疗的患者(94%)均治愈或改善。治疗开始后第8天重复进行血培养显示,阿奇霉素组100%的患者病原体被清除,氯霉素组94%的患者病原体被清除。到第14天,氯霉素组的清除率增至97%。治疗开始后第21天和第35天的粪便培养显示,两组均无沙门菌属粪便携带时间延长的情况。这些结果表明,在耐氯霉素伤寒沙门菌感染流行地区,阿奇霉素每日一次给药7天是治疗伤寒热的有效疗法,且对氯霉素敏感感染患者的疗效与氯霉素相当。